1. Prospective validation of the ASIG PAH screening algorithm
One of ASIG’s key activities is the Australian Scleroderma Screening Program for early identification of heart and lung complications, such as pulmonary arterial hypertension (PAH).
We have developed and validated a novel, cost-effective screening algorithm for PAH, using...
30 January, 2018